Stayble Therapeutics AB (ST:STABL) — Market Cap & Net Worth
Market Cap & Net Worth: Stayble Therapeutics AB (STABL)
Stayble Therapeutics AB (ST:STABL) has a market capitalization of $271.50K (Skr2.52 Million) as of May 4, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #30734 globally and #731 in its home market, demonstrating a 18.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Stayble Therapeutics AB's stock price Skr0.04 by its total outstanding shares 64359792 (64.36 Million). Analyse STABL operating cash flow to see how efficiently the company converts income to cash.
Stayble Therapeutics AB Market Cap History: 2020 to 2026
Stayble Therapeutics AB's market capitalization history from 2020 to 2026. Data shows change from $68.29 Million to $271.50K (-59.18% CAGR).
Index Memberships
Stayble Therapeutics AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 0.00% | #253 of 281 |
Weight: Stayble Therapeutics AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Stayble Therapeutics AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Stayble Therapeutics AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of STABL by Market Capitalization
Companies near Stayble Therapeutics AB in the global market cap rankings as of May 4, 2026.
Key companies related to Stayble Therapeutics AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Stayble Therapeutics AB Historical Marketcap From 2020 to 2026
Between 2020 and today, Stayble Therapeutics AB's market cap moved from $68.29 Million to $ 271.50K, with a yearly change of -59.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr271.50K | -82.58% |
| 2025 | Skr1.56 Million | -55.88% |
| 2024 | Skr3.53 Million | +68.32% |
| 2023 | Skr2.10 Million | -92.42% |
| 2022 | Skr27.70 Million | -36.71% |
| 2021 | Skr43.77 Million | -35.90% |
| 2020 | Skr68.29 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Stayble Therapeutics AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $271.50K USD |
| MoneyControl | $271.50K USD |
| MarketWatch | $271.50K USD |
| marketcap.company | $271.50K USD |
| Reuters | $271.50K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.